Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01055314 · OUTCOME

Event-Free Survival

Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma · Source last updated 2017-08-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Probability
Interval / dispersion
95% Confidence Interval
Time frame
3 years

What was measured

Probability of no relapse, secondary malignancy, or death after 3 years in the study.

Analysis population: 9 participants who were ineligible or did not receive treatment were excluded.

Groups in this outcome

IMC-A12

IMC-A12 + Multi-agent intensive chemotherapy regimen.

Temozolomide

Add temozolomide to vincristine/irinotecan cycles.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
IMC-A1296
Temozolomide70

Reported measurements

Source class 1
Values in Probability · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
IMC-A120.1627Not reported0.07470.2507Not reported
Temozolomide0.1919Not reported0.04070.3431Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.0747
        upper Limit
        0.2507
        value
        0.1627
      2. group Id
        OG001
        lower Limit
        0.0407
        upper Limit
        0.3431
        value
        0.1919
denoms
  1. counts
    1. group Id
      OG000
      value
      96
    2. group Id
      OG001
      value
      70
    units
    Participants
description
Probability of no relapse, secondary malignancy, or death after 3 years in the study.
dispersion Type
95% Confidence Interval
groups
  1. description
    IMC-A12 + Multi-agent intensive chemotherapy regimen.
    id
    OG000
    title
    IMC-A12
  2. description
    Add temozolomide to vincristine/irinotecan cycles.
    id
    OG001
    title
    Temozolomide
param Type
NUMBER
population Description
9 participants who were ineligible or did not receive treatment were excluded.
reporting Status
POSTED
time Frame
3 years
title
Event-Free Survival
type
PRIMARY
unit Of Measure
Probability

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice